Wednesday, May 04, 2022 CCTG congratulates BC Cancer Vancouver GCC1 Trial Team whose work was recognized with the 2022 CCTG Phase III Team Award, for performance in trial accrual, local activation timelines, compliance metrics and team performance. "We are very glad to have received the 2022 CCTG Phase III Team Award for the GCC.1 clinical trial! GCC.1 is a unique exclusive biomarker validating study that has the potential to change clinical practice intesticular germ cell tumors. It is impressive that a clinical trial in a relatively uncommon tumor such as testis cancer is accruing so fast. I thank everyone in our team for believing in and supporting this study and our patients for their availability and help to improve testis cancer care". Kudos to the entire team: Dr. Lucia Nappi, Vivian Shen, Dr. Daniel Khalaf, Dr. Bernie Eigl, Dr. Maryam Soleimani, Dr. Christian Kollmannsberger, Jackie Cao, Dr. Kim Chi, Hae Jung Min, NP Nikita Ivanov, Dr. Corinne Maurice Dror, Dr. Antoine Morin Coulombe, Lisa Rebane
